custirsen + mitoxantrone + prednisone

This is a **combination therapy** consisting of **custirsen (OGX-011), mitoxantrone, and prednisone**, investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed after first-line docetaxel therapy[2][3]. - **Custirsen (OGX-011)** is an **antisense oligonucleotide** that inhibits the production of clusterin, an antiapoptotic protein upregulated in response to chemotherapy and associated with treatment resistance[2][3]. - **Mitoxantrone** is a **small molecule, anthracenedione antineoplastic agent** that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. - **Prednisone** is a **synthetic glucocorticoid corticosteroid** with anti-inflammatory and immunosuppressive properties, commonly used as an adjunct in cancer protocols to reduce inflammation and support tolerance to chemotherapy. This combination was studied as **second-line therapy** for patients with metastatic castration-resistant prostate cancer after progression on docetaxel[2][3]. In phase II trials, this regimen demonstrated feasibility, with pain relief and PSA (prostate-specific antigen) declines, although objective responses were marginal and overall survival in the mitoxantrone arm was lower than in the docetaxel arm[3]. Custirsen combinations were generally well tolerated but appeared less effective with mitoxantrone than with docetaxel[2][3].

Other names

custirsen + mitoxantrone + prednisone